Ads
related to: Biotech Stocks To Buy
Search results
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
WROC Rochester· 3 days agoWith sufferers of these types of cancers seemingly getting younger, and at increased danger for...
3 High-Flying Stocks That Could Soar Even More
Motley Fool via Yahoo Finance· 6 days agoBut it has been expanding its horizons. ... several other drug candidates are in the earlier phases of development. The biotech should make meaningful...
Exelixis director and Caligan Partners LP buy $8.73 million in shares By Investing.com
Investing.com· 8 hours agoIn a recent move, David Edward Johnson, a director at Exelixis, Inc. (NASDAQ:EXEL), and investment...
Down 72%. Is Ginkgo Bioworks a Buy on the Dip?
The Motley Fool via AOL· 6 days agoBioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry...needs a little more time for ...
Should You Buy This Stock After a Regulatory Setback? | The Motley Fool
The Motley Fool· 5 days agoThe past two-and-a-half years have been rough for Moderna (MRNA 1.58%). The company is developing...
Cathie Wood's ARK sheds Robinhood stock, adds to AMD and Guardant Health By Investing.com
Investing.com· 1 day agoCathie Wood's ARK sheds Robinhood stock, adds to AMD and Guardant Health
5 Small Drug Stocks to Buy From a Recovering Industry
Zacks via Yahoo Finance· 7 days agoInnovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX,...
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
Zacks· 2 days agoJ&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Zacks via Yahoo Finance· 16 hours agoMerck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...
The Massive Deal That Could Send This Biotech Into A Break Out
Investor's Business Daily· 3 days agoAgios Pharmaceuticals (AGIO) agreed Tuesday to sell its 15% royalty in a brain cancer drug to...
